"A deeper dive into data from the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) with the type 2 diabetes drug sitagliptin (Januvia, Merck), confirming that the dipeptidyl peptidase-4 (DPP-4) is not associated with any "...
Mechanism Of Action
In vitro, preclinical, and clinical tests have demonstrated that GENOTROPIN lyophilized powder is therapeutically equivalent to human growth hormone of pituitary origin and achieves similar pharmacokinetic profiles in normal adults. In pediatric patients who have growth hormone deficiency (GHD), have Prader-Willi syndrome (PWS), were born small for gestational age (SGA), have Turner syndrome (TS), or have Idiopathic short stature (ISS), treatment with GENOTROPIN stimulates linear growth. In patients with GHD or PWS, treatment with GENOTROPIN also normalizes concentrations of IGF-I (Insulin-like Growth Factor-I/Somatomedin C). In adults with GHD, treatment with GENOTROPIN results in reduced fat mass, increased lean body mass, metabolic alterations that include beneficial changes in lipid metabolism, and normalization of IGF-I concentrations.
In addition, the following actions have been demonstrated for GENOTROPIN and/or somatropin.
- Skeletal Growth: GENOTROPIN stimulates skeletal growth in pediatric patients with GHD, PWS, SGA, TS, or ISS. The measurable increase in body length after administration of GENOTROPIN results from an effect on the epiphyseal plates of long bones. Concentrations of IGF-I, which may play a role in skeletal growth, are generally low in the serum of pediatric patients with GHD, PWS, or SGA, but tend to increase during treatment with GENOTROPIN. Elevations in mean serum alkaline phosphatase concentration are also seen.
- Cell Growth: It has been shown that there are fewer skeletal muscle cells in short-statured pediatric patients who lack endogenous growth hormone as compared with the normal pediatric population. Treatment with somatropin results in an increase in both the number and size of muscle cells.
Linear growth is facilitated in part by increased cellular protein synthesis. Nitrogen retention, as demonstrated by decreased urinary nitrogen excretion and serum urea nitrogen, follows the initiation of therapy with GENOTROPIN.
Pediatric patients with hypopituitarism sometimes experience fasting hypoglycemia that is improved by treatment with GENOTROPIN. Large doses of growth hormone may impair glucose tolerance.
In GHD patients, administration of somatropin has resulted in lipid mobilization, reduction in body fat stores, and increased plasma fatty acids.
Somatropin induces retention of sodium, potassium, and phosphorus. Serum concentrations of inorganic phosphate are increased in patients with GHD after therapy with GENOTROPIN. Serum calcium is not significantly altered by GENOTROPIN. Growth hormone could increase calciuria.
Adult GHD patients treated with GENOTROPIN at the recommended adult dose (see DOSAGE AND ADMINISTRATION) demonstrate a decrease in fat mass and an increase in lean body mass. When these alterations are coupled with the increase in total body water, the overall effect of GENOTROPIN is to modify body composition, an effect that is maintained with continued treatment.
Following a 0.03 mg/kg subcutaneous (SC) injection in the thigh of 1.3 mg/mL GENOTROPIN to adult GHD patients, approximately 80% of the dose was systemically available as compared with that available following intravenous dosing. Results were comparable in both male and female patients. Similar bioavailability has been observed in healthy adult male subjects.
In healthy adult males, following an SC injection in the thigh of 0.03 mg/kg, the extent of absorption (AUC) of a concentration of 5.3 mg/mL GENOTROPIN was 35% greater than that for 1.3 mg/mL GENOTROPIN. The mean (± standard deviation) peak (Cmax) serum levels were 23.0 (± 9.4) ng/mL and 17.4 (± 9.2) ng/mL, respectively.
In a similar study involving pediatric GHD patients, 5.3 mg/mL GENOTROPIN yielded a mean AUC that was 17% greater than that for 1.3 mg/mL GENOTROPIN. The mean Cmax levels were 21.0 ng/mL and 16.3 ng/mL, respectively.
Adult GHD patients received two single SC doses of 0.03 mg/kg of GENOTROPIN at a concentration of 1.3 mg/mL, with a one-to four-week washout period between injections. Mean Cmax levels were 12.4 ng/mL (first injection) and 12.2 ng/mL (second injection), achieved at approximately six hours after dosing.
There are no data on the bioequivalence between the 12 mg/mL formulation and either the 1.3 mg/mL or the 5.3 mg/mL formulations.
The mean volume of distribution of GENOTROPIN following administration to GHD adults was estimated to be 1.3 (± 0.8) L/kg.
The metabolic fate of GENOTROPIN involves classical protein catabolism in both the liver and kidneys. In renal cells, at least a portion of the breakdown products are returned to the systemic circulation. The mean terminal half-life of intravenous GENOTROPIN in normal adults is 0.4 hours, whereas subcutaneously administered GENOTROPIN has a half-life of 3.0 hours in GHD adults. The observed difference is due to slow absorption from the subcutaneous injection site.
The mean clearance of subcutaneously administered GENOTROPIN in 16 GHD adult patients was 0.3 (± 0.11) L/hrs/kg.
Pediatric: The pharmacokinetics of GENOTROPIN are similar in GHD pediatric and adult patients.
Gender: No gender studies have been performed in pediatric patients; however, in GHD adults, the absolute bioavailability of GENOTROPIN was similar in males and females.
Race: No studies have been conducted with GENOTROPIN to assess pharmacokinetic differences among races.
Renal or hepatic insufficiency: No studies have been conducted with GENOTROPIN in these patient populations.
Table 2 : Mean SC Pharmacokinetic Parameters in Adult
|Bioavaila bility (%)
|CL/F (L/hr x kg)
|Mean(± SD)||80.5*||5.9 (± 1.65)||0.3 (± 0.11)||1.3 (± 0.80)||3.0 (± 1.44)|
|95% CI||70.5 -92.1||5.0 - 6.7||0.2 - 0.4||0.9 - 1.8||2.2 - 3.7|
|Tmax = time of maximum plasma
T ½ = terminal half-life
CL/F = plasma clearance
SD = standard deviation
Vss/F = volume of distribution
CI = confidence interval
* The absolute bioavailability was estimated under the assumption that the log-transformed data follow a normal distribution. The mean and standard deviation of the log-transformed data were mean = 0.22 (± 0.241).
Adult Growth Hormone Deficiency (GHD)
GENOTROPIN lyophilized powder was compared with placebo in six randomized clinical trials involving a total of 172 adult GHD patients. These trials included a 6month double-blind treatment period, during which 85 patients received GENOTROPIN and 87 patients received placebo, followed by an open-label treatment period in which participating patients received GENOTROPIN for up to a total of 24 months. GENOTROPIN was administered as a daily SC injection at a dose of 0.04 mg/kg/week for the first month of treatment and 0.08 mg/kg/week for subsequent months.
Beneficial changes in body composition were observed at the end of the 6-month treatment period for the patients receiving GENOTROPIN as compared with the placebo patients. Lean body mass, total body water, and lean/fat ratio increased while total body fat mass and waist circumference decreased. These effects on body composition were maintained when treatment was continued beyond 6 months. Bone mineral density declined after 6 months of treatment but returned to baseline values after 12 months of treatment.
Prader-Willi Syndrome (PWS)
The safety and efficacy of GENOTROPIN in the treatment of pediatric patients with Prader-Willi syndrome (PWS) were evaluated in two randomized, open-label, controlled clinical trials. Patients received either GENOTROPIN or no treatment for the first year of the studies, while all patients received GENOTROPIN during the second year. GENOTROPIN was administered as a daily SC injection, and the dose was calculated for each patient every 3 months. In Study 1, the treatment group received GENOTROPIN at a dose of 0.24 mg/kg/week during the entire study. During the second year, the control group received GENOTROPIN at a dose of 0.48 mg/kg/week. In Study 2, the treatment group received GENOTROPIN at a dose of 0.36 mg/kg/week during the entire study. During the second year, the control group received GENOTROPIN at a dose of 0.36 mg/kg/week.
Patients who received GENOTROPIN showed significant increases in linear growth during the first year of study, compared with patients who received no treatment (see Table 3). Linear growth continued to increase in the second year, when both groups received treatment with GENOTROPIN.
Table 3 : Efficacy of GENOTROPIN in Pediatric Patients
with Prader-Willi Syndrome (Mean ± SD)
|Study 1||Study 2|
|GENOTR OPIN (0.24 mg/kg/week)
|GENOTR OPIN (0.36 mg/kg/week)
|Linear growth (cm)|
|Baseline height||112.7 ± 14.9||109.5 ± 12.0||120.3 ± 17.5||120.5 ± 11.2|
|Growth from months 0 to 12||11.6* ± 2.3||5.0 ± 1.2||10.7* ± 2.3||4.3 ± 1.5|
|Height Standard Deviation Score (SDS) for age|
|Baseline SDS||-1.6 ± 1.3||-1.8 ± 1.5||-2.6 ± 1.7||-2.1 ± 1.4|
|SDS at 12 months||-0.5*± 1.3||-1.9 ± 1.4||-1.4* ± 1.5||-2.2 ± 1.4|
|* p ≤ 0.001
† p ≤ 0.002 (when comparing SDS change at 12 months)
Changes in body composition were also observed in the patients receiving GENOTROPIN (see Table 4). These changes included a decrease in the amount of fat mass, and increases in the amount of lean body mass and the ratio of lean-to-fat tissue, while changes in body weight were similar to those seen in patients who received no treatment. Treatment with GENOTROPIN did not accelerate bone age, compared with patients who received no treatment.
Table 4 : Effect of
GENOTROPIN on Body Composition in Pediatric Patients with Prader-Willi Syndrome
(Mean ± SD)
|Fat mass (kg)|
|Baseline||12.3 ± 6.8||9.4 ± 4.9|
|Change from months 0 to 12||-0.9* ± 2.2||2.3 ± 2.4|
|Lean body mass (kg)|
|Baseline||15.6 ± 5.7||14.3 ± 4.0|
|Change from months 0 to 12||4.7* ± 1.9||0.7 ± 2.4|
|Lean body mass/Fat mass|
|Baseline||1.4 ± 0.4||1.8 ± 0.8|
|Change from months 0 to 12||1.0* ± 1.4||-0.1 ± 0.6|
|Body weight (kg) †|
|Baseline||27.2 ± 12.0||23.2 ± 7.0|
|Change from months 0 to 12||3.7‡ ± 2.0||3.5 ± 1.9|
|* p < 0.005
† n=15 for the group receiving GENOTROPIN; n=12 for the Control group
Pediatric Patients Born Small for Gestational Age (SGA) Who Fail to Manifest Catch-up Growth by Age 2
The safety and efficacy of GENOTROPIN in the treatment of children born small for gestational age (SGA) were evaluated in 4 randomized, open-label, controlled clinical trials. Patients (age range of 2 to 8 years) were observed for 12 months before being randomized to receive either GENOTROPIN (two doses per study, most often 0.24 and 0.48 mg/kg/week) as a daily SC injection or no treatment for the first 24 months of the studies. After 24 months in the studies, all patients received GENOTROPIN.
Patients who received any dose of GENOTROPIN showed significant increases in growth during the first 24 months of study, compared with patients who received no treatment (see Table 5). Children receiving 0.48 mg/kg/week demonstrated a significant improvement in height standard deviation score (SDS) compared with children treated with 0.24 mg/kg/week. Both of these doses resulted in a slower but constant increase in growth between months 24 to 72 (data not shown).
Table 5 : Efficacy of
GENOTROPIN in Children Born Small for Gestational Age (Mean ± SD)
|GENOTRO PIN (0.24 mg/kg/week)
|GENOTRO PIN (0.48 mg/kg/week)
|Height Standard Deviation Score (SDS)|
|Baseline SDS||-3.2 ± 0.8||-3.4 ± 1.0||-3.1 ± 0.9|
|SDS at 24 months||-2.0 ± 0.8||-1.7 ± 1.0||-2.9 ± 0.9|
|Change in SDS from baseline to month 24||1.2* ± 0.5||1.7*† ± 0.6||0.1 ± 0.3|
|* p = 0.0001 vs Untreated Control group
† p = 0.0001 vs group treated with GENOTROPIN 0.24 mg/kg/week
Two randomized, open-label, clinical trials were conducted that evaluated the efficacy and safety of GENOTROPIN in Turner syndrome patients with short stature. Turner syndrome patients were treated with GENOTROPIN alone or GENOTROPIN plus adjunctive hormonal therapy (ethinylestradiol or oxandrolone). A total of 38 patients were treated with GENOTROPIN alone in the two studies. In Study 055, 22 patients were treated for 12 months, and in Study 092, 16 patients were treated for 12 months. Patients received GENOTROPIN at a dose between 0.13 to 0.33 mg/kg/week.
SDS for height velocity and height are expressed using either the Tanner (Study 055) or Sempé (Study 092) standards for age-matched normal children as well as the Ranke standard (both studies) for age-matched, untreated Turner syndrome patients. As seen in Table 5, height velocity SDS and height SDS values were smaller at baseline and after treatment with GENOTROPIN when the normative standards were utilized as opposed to the Turner syndrome standard.
Both studies demonstrated statistically significant increases from baseline in all of the linear growth variables (i.e., mean height velocity, height velocity SDS, and height SDS) after treatment with GENOTROPIN (see Table 6). The linear growth response was greater in Study 055 wherein patients were treated with a larger dose of GENOTROPIN.
Table 6 : Growth Parameters (mean ± SD) after 12
Months of Treatment with GENOTROPIN in Pediatric Patients with Turner Syndrome
in Two Open Label Studies
|GENOTROPIN 0.33 mg/kg/week Study 055^
|GENOTROPIN 0.13-0.23 mg/kg/week Study 092#
|Height Velocity (cm/yr)|
|Baseline||4.1 ± 1.5||3.9 ± 1.0|
|Month 12||7.8 ± 1.6||6.1 ± 0.9|
|Change from baseline (95% CI)||3.7 (3.0, 4.3)||2.2 (1.5, 2.9)|
|Height Velocity SDS (Tanner^/Sempe# Standards)||(n=20)|
|Baseline||-2.3 ± 1.4||-1.6 ± 0.6|
|Month 12||2.2 ± 2.3||0.7 ± 1.3|
|Change from baseline (95% CI)||4.6 (3.5, 5.6)||2.2 (1.4, 3.0)|
|Height Velocity SDS (Ranke Standard)|
|Baseline||-0.1 ± 1.2||-0.4 ± 0.6|
|Month 12||4.2 ± 1.2||2.3 ± 1.2|
|Change from baseline (95% CI)||4.3 (3.5, 5.0)||2.7 (1.8, 3.5)|
|Height SDS (T annerA/Sempe# Standards)|
|Baseline||-3.1 ± 1.0||-3.2 ± 1.0|
|Month 12||-2.7 ± 1.1||-2.9 ± 1.0|
|Change from baseline (95% CI)||0.4 (0.3, 0.6)||0.3 (0.1, 0.4)|
|Height SDS (Ranke Standard)|
|Baseline||-0.2 ± 0.8||-0.3 ± 0.8|
|Month 12||0.6 ± 0.9||0.1 ± 0.8|
|Change from baseline (95% CI)||0.8 (0.7, 0.9)||0.5 (0.4, 0.5)|
|SDS = Standard Deviation Score
Ranke standard based on age-matched, untreated Turner syndrome patients
Tanner^/Sempé# standards based on age-matched normal children
p < 0.05, for all changes from baseline
Idiopathic Short Stature
The long-term efficacy and safety of GENOTROPIN in patients with idiopathic short stature (ISS) were evaluated in one randomized, open-label, clinical trial that enrolled 177 children. Patients were enrolled on the basis of short stature, stimulated GH secretion > 10 ng/mL, and prepubertal status (criteria for idiopathic short stature were retrospectively applied and included 126 patients). All patients were observed for height progression for 12 months and were subsequently randomized to Genotropin or observation only and followed to final height. Two Genotropin doses were evaluated in this trial: 0.23 mg/kg/week (0.033 mg/kg/day) and 0.47 mg/kg/week (0.067 mg/kg/day). Baseline patient characteristics for the ISS patients who remained prepubertal at randomization (n= 105) were: mean (± SD): chronological age 11.4 (1.3) years, height SDS -2.4 (0.4), height velocity SDS -1.1 (0.8), and height velocity 4.4 (0.9) cm/yr, IGF-1 SDS -0.8 (1.4). Patients were treated for a median duration of 5.7 years. Results for final height SDS are displayed by treatment arm in Table 7. GENOTROPIN therapy improved final height in ISS children relative to untreated controls. The observed mean gain in final height was 9.8 cm for females and 5.0 cm for males for both doses combined compared to untreated control subjects. A height gain of 1 SDS was observed in 10 % of untreated subjects, 50% of subjects receiving 0.23 mg/kg/week and 69% of subjects receiving 0.47 mg/kg/week
Table 7: Final height SDS
results for pre-pubertal patients with ISS*
|GEN 0.033 vs. Untreated (95% CI)||GEN 0.067 vs. Untreated (95% CI)|
|Baseline height SDS Final height SDS minus baseline||0.41 (0.58)||0.95 (0.75)||1.36 (0.64)||+0.53 (0.20, 0.87) p=0.0022||+0.94 (0.63, 1.26) p < 0.0001|
|Baseline predicted ht Final height SDS minus baseline predicted final height SDS||0.23 (0.66)||0.73 (0.63)||1.05 (0.83)||+0.60 (0.09, 1.11) p=0.0217||+0.90 (0.42, 1.39) p=0.0004|
|*Mean (SD) are observed values.
**Least square means based on ANCOVA (final height SDS and final height SDS minus baseline predicted height SDS were adjusted for baseline height SDS)
Last reviewed on RxList: 7/15/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Genotropin Information
Genotropin - User Reviews
Genotropin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.